“It's well known that sensitivity is a major driver of commercial success and value for point-of-care tests,” said Jim Kadushin, Genisphere's Chief Operating Officer. “Genisphere's new process for ...

Dr. Mindy George-Weinstein, Professor of Biomedical Sciences at the Cooper Medical School of Rowan University, stated, "Myo/Nog cells have also been found in a variety of tumors, where we predict they ...

HATFIELD, Pa., June 30, 2015 /PRNewswire/ -- Genisphere announced Tom Bliss has joined the company as CEO to help further develop Genisphere's therapeutics capabilities and portfolio. Mr. Bliss comes ...

HATFIELD, Pa.--(BUSINESS WIRE)--Genisphere LLC, provider of the 3DNA ® nanotechnology platform, reported today it has closed $2 million in private funding from existing investors, including Corporate ...

HATFIELD, Pa., Nov. 1, 2019 /PRNewswire/ -- Genisphere reported a publication in the journal Brain that demonstrates a novel 3DNA® nanocarrier shown to carry a peptide drug through the body and ...

HATFIELD, Pa.--(BUSINESS WIRE)--Genisphere LLC has licensed its 3DNA® Signal Amplification technology to Chembio Diagnostics, Inc., a leader in point-of-care ("POC") diagnostic tests for infectious ...

HATFIELD, Penn., Oct. 1, 2015 /PRNewswire/ -- Genisphere LLC, provider of the 3DNA® nanotechnology platform, announced it has closed a $4mm equity round. This round of fundraising will extend and ...

Genisphere LLC reported today it has been granted a US patent for a novel strand-specific library preparation method for next generation sequencing based on its proven RNA amplification technology.

HATFIELD, Pa., Dec. 6, 2018 /PRNewswire/ -- Genisphere LLC, provider of the 3DNA ® nanotechnology drug delivery platform, announced Brian P. McVeigh has joined the company's Board of Directors, ...

Genisphere will partner with the University of Maryland to study the pharmacokinetics and pharmacodynamics of various designs and formulations after in vivo administration of its 3DNA ® targeted drug ...

HATFIELD, Pa., March 26, 2015 /PRNewswire/ -- Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has achieved specific immunodepletion of problematic Myo/Nog cells ...

Graphical representation of the 3DNA-based therapeutic used in the studies. The 3DNA nanocarrier is labeled with fluorescent dye for visualization and carries the peptide drug. HATFIELD, Pa., Nov. 1, ...